Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.63 |
| ▸ | MEN1 | O00255 | 6/20 | 0.60 |
| ▸ | KMT2A | Q03164 | 6/20 | 0.60 |
| ▸ | MAPT | P10636 | 7/20 | 0.59 |
| ▸ | ALDH1A1 | P00352 | 6/20 | 0.59 |
| ▸ | L3MBTL1 | Q9Y468 | 4/20 | 0.58 |
| ▸ | SMN1; SMN2 | Q16637 | 4/20 | 0.58 |
| ▸ | LMNA | P02545 | 2/20 | 0.57 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.56 |
| ▸ | PKM | P14618 | 1/20 | 0.53 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.53 |
| ▸ | HTT | P42858 | 1/20 | 0.53 |
| ▸ | GAA | P10253 | 2/20 | 0.53 |
| ▸ | RAB9A | P51151 | 1/20 | 0.53 |
| ▸ | POLB | P06746 | 1/20 | 0.53 |
| ▸ | CASP6 | P55212 | 1/20 | 0.53 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5110422 | 0.78 | SLC10A6 (0.62) | MEN1KMT2AMAPTALDH1A1SMN1; SMN2 | |
| SCHEMBL5111331 | 0.78 | LMNA (0.62) | KDM4EMEN1KMT2AMAPTALDH1A1 | |
| SCHEMBL491806 | 0.74 | SLC10A6 (0.54) | KDM4EMEN1KMT2AMAPTALDH1A1 | |
| SCHEMBL491931 | 0.74 | KMT2A (0.72) | KDM4EMEN1KMT2AMAPTALDH1A1 | |
| SCHEMBL492051 | 0.73 | KMT2A (0.59) | KDM4EMEN1KMT2AALDH1A1L3MBTL1 | |
| SCHEMBL13146557 | 0.72 | KDM4E (0.59) | KDM4EALDH1A1L3MBTL1SMN1; SMN2LMNA | |
| SCHEMBL5111944 | 0.72 | SLC10A6 (0.59) | MEN1KMT2AMAPTALDH1A1SMN1; SMN2 | |
| SCHEMBL9920141 | 0.72 | KDM4E (0.79) | KDM4EMEN1KMT2AMAPTALDH1A1 | |
| SCHEMBL5111933 | 0.71 | MAPT (0.71) | MEN1KMT2AMAPTALDH1A1L3MBTL1 | |
| SCHEMBL492472 | 0.71 | KMT2A (0.67) | KDM4EMEN1KMT2AMAPTALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7351703-B2 | Sulfonylamino carboxylic acid N-arylamides as guanylate cyclase activators | SANOFI-AVENTIS DEUTSCHLAND GMBH (DE) | 2008-04-01 | — | — | US | disclosed |
| EP-1095015-B1 | SULFONYLAMINO CARBOXYLIC ACID N-ARYLAMIDES AS GUANYLATE CYCLASE ACTIVATORS | AVENTIS PHARMA GMBH (DE) | 2005-06-01 | — | — | EP | disclosed |
| US-20050080073-A1 | Sulfonylaminocarboxiylic acid N-arylamides as guanylate cyclase activators | AVENTIS PHARMA DEUTSCHLAND GMBH | 2005-04-14 | — | — | US | disclosed |
| US-6809089-B2 | FOR THERAPY AND PROPHYLAXIS OF CARDIOVASCULAR DISORDERS SUCH AS HIGH BLOOD PRESSURE, ANGINA PECTORIS, CARDIAC INSUFFICIENCY, THROMBOSES OR ATHEROSCLEROSIS | AVENTIS PHARMA DEUTSCHLAND GMBH (DE) | 2004-10-26 | — | — | US | disclosed |
| US-20030171352-A1 | Sulfonylaminocarboxylic acid N-arylamides as guanylate cyclase activators | AVENTIS PHARMA DEUTSCHLAND GMBH | 2003-09-11 | — | — | US | disclosed |
| US-6548547-B1 | Cardiovascular disorders; hypotensive agents, antiasthmatics, cognition activators | AVENTIS PHARMA DEUTSCHLAND GMBH (DE) | 2003-04-15 | — | — | US | disclosed |
| EP-1095015-A2 | SULFONYLAMINO CARBOXYLIC ACID N-ARYLAMIDES AS GUANYLATE CYCLASE ACTIVATORS | Aventis Pharma Deutschland GmbH (DE) | 2001-05-02 | — | — | EP | disclosed |
| WO-2000002850-A2 | SULFONYLAMINO CARBOXYLIC ACID N-ARYLAMIDES AS GUANYLATE CYCLASE ACTIVATORS | AVENTIS PHARMA DEUTSCHLAND GMBH (DE) | 2000-01-20 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050080073-A1 | Sulfonylaminocarboxiylic acid N-arylamides as guanylate cyclase activators | GUCY1A1, GUCY1B1, GUCY1A2 | KDM4E 4187/4885MEN1 3114/4885KMT2A 3785/4885 |
| US-20030171352-A1 | Sulfonylaminocarboxylic acid N-arylamides as guanylate cyclase activators | GUCY1A1, GUCY1B1, GUCY1B2 | KDM4E 3666/4885MEN1 3892/4885KMT2A 4155/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.